Samsung Bioepis Turns Net Loss to Net Profit After Restating Consolidated Financial Statements

Samsung Bioepis reissued its audit report for FY2025 after restating consolidated financial statements (date changed from 2026.3.4 to 2026.5.15)
Net loss of 31.4 billion KRW revised to net profit of 85.3 billion KRW (attributable to owners of the parent same)
Total liabilities decreased from 1.93 trillion KRW to 1.81 trillion KRW; total equity increased from 5.79 trillion KRW to 5.91 trillion KRW (no non-controlling interests)
Audit opinion: unqualified; no going concern uncertainty
Separate financial statements: assets 3.35 trillion KRW, liabilities 11.9 billion KRW, equity 3.34 trillion KRW, net loss 1.8 billion KRW (2-month post-demerger results)
No capital impairment (capital stock 62.2 billion KRW vs. total equity 5.91 trillion KRW)
Established on Nov 1, 2025 via spin-off from Samsung Biologics)